Skip to main content

Day: February 22, 2022

Confirmation of the restructuring plan of Swencn AB (a subsidiary of Nordecon AS)

On 21 February 2022, the Nacka District Court in Stockholm confirmed a restructuring plan approved by the creditors of Swencn AB (a Nordecon Group company operating in Sweden), according to which Swencn AB’s creditors’ claims are payable in the extent of 25% of their claims within six months of court confirmation of the restructuring plan. It is not a transaction that goes beyond the scope of day-to-day business or is of significant importance within the meaning of the section “Requirements for Issuers” of the regulations of the Nasdaq Tallinn Stock Exchange. Andri HõbemägiNordecon ASHead of Investor RelationsTel: +372 6272 022Email: andri.hobemagi@nordecon.comwww.nordecon.com

Continue reading

Avance Gas Holding Ltd Reports Unaudited Results for the Fourth Quarter of 2021

BERMUDA, 22 February 2022 – Avance Gas Holding Ltd (OSE: AGAS or the “Company”) today reported unaudited results for the fourth quarter 2021. HIGHLIGHTSThe average time charter equivalent (TCE) rate was $27,631/day compared to $27,548/day in Q3 2021. The full year 2021 TCE rate was $31,302/day compared to $32,418/day in 2020. Daily operating expenses (OPEX) were $8,139/day, down from $8,610/day in Q3 2021. Full year 2021 OPEX was $8,871/day, down from $8,968/day in 2020. A&G expenses were $1,351/day, down from $1,549/day in Q3 2021. Full year 2021 A&G expenses were $1,363/day, up from $771/day in 2020. In December 2021, the Company successfully executed a sale leaseback transaction of the VLGC Iris Glory generating approximately $16.6 million in net cash proceeds. In January 2022, the Company took delivery of Avance Polaris,...

Continue reading

Pixium Vision announces its unaudited financial results for 2021 and provides a business update

        Pixium Vision announces its unaudited financial results for 2021 and provides a business updateCash position on 31 December 2021: €14.5 million Cash runway to end of Q4 2022 Clinical development, activating multiple clinical sites and successfully implanting patients enrolled in our PRIMAvera pivotal studyParis, 22 February 2022 – 7.00 a.m. CET – Pixium Vision (FR0011950641 – PIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces its financial results for 2021 and provides a business update. The 2021 financial statements were approved by Pixium Vision’s Board of Directors at its meeting on 17 February 2022. Lloyd Diamond, CEO of Pixium Vision commented “In 2021, we continued to deliver on our promises, and...

Continue reading

Worldline – FY 2021 results

FY 2021 continued operations results: all objectives reachedwith strong growth acceleration in Q4 2021Revenue: € 3,689 million, +6.8% organicallyOMDA: € 933 million, 25.3% of revenue, +220 bpsFree cash flow: € 407 million, 43.6% OMDA conversion Full execution of the strategic roadmapFirst year of integration of Ingenico generating synergies fully in line with expectationsMerchant Services expanding in attractive geographies through market consolidation Binding offer received from Apollo to divest terminal activities 2022 objectives fully in line with three-year targets8% to 10% revenue organic growth100 to 150 bps OMDA margin improvement vs. 2021 proformaCirca 45% OMDA conversion to FCF Paris La Défense, February 22, 2022 – Worldline [Euronext: WLN], a leader in the payments industry, today announces its 2021 annual results. Gilles Grapinet,...

Continue reading

Norsk Hydro: Record results in Q4 and full year 2021

Norsk Hydro ASA posted fourth-quarter 2021 EBITDA of NOK 9,011 million, compared with NOK 3,403 million for the same quarter last year. Full-year 2021 EBITDA amounted to NOK 28,010 million, compared with NOK 13,106 million in 2020. – Continued tight markets across aluminium value chain – Record results upstream and in Hydro Energy for Q4 – 2021 improvement program target exceeded by 25% – 2025 strategy execution progressing as planned – 80% cash dividend payment on strong financials Higher all-in metal and alumina prices, improved volumes upstream, and record-high quarterly results from Hydro Energy contributed positively to adjusted EBITDA in the fourth quarter. These positive elements were partly offset by higher fixed and raw material costs upstream and negative currency effects. Adjusted EBITDA for the...

Continue reading

Scanfil Group’s Financial Statement 2021: Record high turnover supported by strong customer demand

Scanfil plc     Financial statement     22 February 2022 at 8.00 a.m. EET Scanfil Group’s Financial Statement 2021 Record high turnover supported by strong customer demand October–DecemberTurnover totalled EUR 191.7 million (10-12 2020: 154.1), an increase of 24.5%. Adjusted operating profit was EUR 10.2 (10.4) million, 5.3% (6.8%) of turnover. Operating profit was EUR 9.5 (4.3) million, 5.0% (2.8%) of turnover. Adjusted net profit was EUR 9.1 (9.2) million. Net profit was EUR 8.4 (3.1) million. Adjusted earnings per share were EUR 0.14 (0.14), earnings per share were EUR 0.13 (0.05).January–DecemberTurnover totalled EUR 695.7 million (1-12 2020: 595.3), an increase of 16.9%. Adjusted operating profit was EUR 40.3 (39.1) million, 5.8% (6.6%) of turnover. Operating profit was EUR 39.6 (44.4) million, 5.7% (7.5%) of turnover. Comparison...

Continue reading

mHealth market Size [2022] | to extend USD 293.29 billion by 2028, exhibiting an extraordinary CAGR of 29.1%

The mHealth market size is projected to reach USD 293.29 billion by 2028, exhibiting a CAGR of 29.1% during the forecast period. Pune, India, Feb. 22, 2022 (GLOBE NEWSWIRE) — The mHealth market size is expected to reach USD 293.29 billion by 2028, exhibiting a CAGR of 29.1% during the forecast period.  The increasing penetration of smartphones and smart devices will boost the mHealth market trends during the forecast period 2021-2028 Fortune Business Insights specializes in producing market research reports for the Healthcare industry, offering in-depth analysis of the industry drivers, trends, and restraints, and detailed insights into the future prospects along with a comprehensive evaluation of the historical performance of the industry. Fortune Business Insights provides detailed profiles of the companies operating in this...

Continue reading

Spinal Cord Stimulation Market Size [2022] | to extend USD 4.12 billion by 2028, with a CAGR of 8.0%

Key Prominent Players Covered in the Spinal Cord Stimulation Market are Boston Scientific Corporation (Massachusetts, U.S.), Medtronic (Dublin, Ireland), Abbott (Illinois, U.S.), Nevro Corp (California, U.S.), Nuvectra (Texas, U.S.), Stimwave LLC (Florida, U.S.) Pune, India, Feb. 22, 2022 (GLOBE NEWSWIRE) — The spinal cord stimulation market is projected to hit USD 4.12 billion by 2028, with a CAGR of 8.0% during the forecast period [2022-2028]. The increasing acceptance of minimally invasive therapies can have a tremendous impact on the global market. Fortune Business Insights™ delivers helps clients in coherent decision-making by offering extensive, competitive, & comprehensive reports on all the markets falling under the technology & media sub-domain. The reports consist of growth projections, revenue, share, and niche...

Continue reading

Digital Pathology Market Size [2022-2028] | Industry Size, Share, Growth & Forecast Analysis Report

Key Prominent Players Covered in the Digital Pathology Market Research Report are 3DHISTECH – The Digital Pathology Company, Mikroscan Technologies, Inc., Objective Pathology Services, Hamamatsu Photonics, Roche Diagnostics Danmark, Primera Technology, Biogenuix Medsystems Pvt Ltd and other key market players Pune, India, Feb. 22, 2022 (GLOBE NEWSWIRE) — The global digital pathology market size is expected to grow due to the rising technological advancements in the healthcare sector during the forecast period. Fortune Business Insights™ publishes this information in an upcoming report titled, “Digital Pathology Market, 2021-2028”. At Fortune Business Insights, we offer meticulous studies to help healthcare organizations get into the mind of their customer and design winning growth strategies. Our services therefore...

Continue reading

Foot Orthotic Insoles Market Size [2022] | to extend USD 4.50 billion by 2028 with stunning 6.1% CAGR

Foot Orthotic Insoles Market Covered By Key Companies Implus LLC, Hanger Inc., Aetrex Worldwide, Inc., Footbalance System Ltd., Tynor Orthotics Pvt. Ltd., Digital Orthotics Laboratories Australia Pty Ltd., Thuasne Pune, India, Feb. 22, 2022 (GLOBE NEWSWIRE) — The global foot orthotic insoles market size is expected to reach USD 4.50 billion by 2028. Fortune Business Insights, describes, “Foot Orthotic Insoles Market Size, Share & COVID-19 Impact Analysis, By Type (Prefabricated and Customized), By Application (Medical, Sports & Athletics, and Personal), By Material (Thermoplastics, Ethyl-vinyl Acetate (EVA), Foam, Composite Carbon Fiber, and Others), By Age Group (Pediatrics and Adults), By Distribution Channel (Hospital Pharmacies, Retail Stores, and Online Stores), and Regional Forecast, 2020-2028.”, and  market stood...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.